Drug Profile
Research programme: JAK-STAT pathway inhibitors - CEAMED
Alternative Names: JAKINIBLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator CEAMED
- Class Antineoplastics
- Mechanism of Action Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Cancer in Spain
- 15 Jul 2016 Early research in Cancer in Spain (unspecified route)